• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bioceres Crop Solutions Corp.

    1/25/23 2:32:43 PM ET
    $BIOX
    Agricultural Chemicals
    Industrials
    Get the next $BIOX alert in real time by email
    SC 13G 1 bioceres_13g.htm SC 13G
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Bioceres Crop Solutions Corp.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    G1117K114

     

    (CUSIP Number)

     

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

    SEC 1745 (12-02)

     
     
    CUSIP No. G1117K114 13G Page 2 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Advisory Partners LP

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 1,854,000
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 1,854,000
    9. aggregate amount beneficially owned by each reporting person 1,854,000
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 2.95%
    12. type of reporting person (See Instructions) PN, IA

     

     
    CUSIP No. G1117K114 13G Page 3 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Advisory Partners GP LLC

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 1,854,000
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 1,854,000
    9. aggregate amount beneficially owned by each reporting person 1,854,000
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 2.95%
    12. type of reporting person (See Instructions) OO

     

     
    CUSIP No. G1117K114 13G Page 4 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Partners I GP LLC

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 1,854,000
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 1,854,000
    9. aggregate amount beneficially owned by each reporting person 1,854,000
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 2.95%
    12. type of reporting person (See Instructions) OO

     

     
    CUSIP No. G1117K114 13G Page 5 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Philip J. Hempleman

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 1,854,000
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 1,854,000
    9. aggregate amount beneficially owned by each reporting person 1,854,000
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 2.95%
    12. type of reporting person (See Instructions) IN

     

     
    CUSIP No. G1117K114 13G Page 6 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Partners Renewable Energy Fund, L.P.

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 1,845,000
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 1,845,000
    9. aggregate amount beneficially owned by each reporting person 1,845,000
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 2.94%
    12. type of reporting person (See Instructions) PN

     

     
    CUSIP No. G1117K114 13G Page 7 of 11 Pages

     


    Item 1.
      (a)  Name of Issuer: Bioceres Crop Solutions Corp.
         
      (b)  Address of Issuer’s Principal Executive Offices:

    Ocampo 210 bis

    Predio CCT, Rosario, Santa Fe, Argentina

    Item 2.
      (a)  Name of Person Filing: This Schedule 13G (the “Schedule”) is being filed with respect to shares of Common Stock (as defined below) of Bioceres Crop Solutions Corp. (the “Issuer”) which are beneficially owned by Ardsley Advisory Partners LP (the “Advisor”), Ardsley Advisory Partners GP LLC (the “Advisor General Partner”), Ardsley Partners I GP LLC (the “General Partner”), Phillip J. Hempleman (“Hempleman”), and Ardsley Partners Renewable Energy Fund, L.P. (the “Renewable Energy Fund”, and together with the Advisor, the Advisor General Partner, the General Partner, and Hempleman, collectively, the “Reporting Persons”).  See Item 4 below.  
      (b)  Address of Principal Business Office or, if none, Residence:

    262 Harbor Drive

    Stamford, CT 06902

      (c)  Citizenship: Each of the Advisor and the Renewable Energy Fund is a Delaware limited partnership. Each of the Advisor General Partner and the General Partner is a Delaware limited liability company. Hempleman is a United States Citizen.
      (d)  Title of Class of Securities: Common Stock
      (e)  CUSIP Number: G1117K114
               

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     
    CUSIP No. G1117K114 13G Page 8 of 11 Pages

     

    Item 4.              Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.    

    The Information required by Items 4(a) - (c) is set forth in Rows 5-11 of the cover page for each Reporting Person hereto and is incorporated by reference for each Reporting Person. The percentage ownership of the Reporting Persons is based on the 62,796,693 outstanding shares of Common Stock of the Issuer, as disclosed on the Issuer’s Rule 424(b)(3) Prospectus dated November 18, 2022, filed with the SEC on November 18, 2022.  

     

    The Reporting Persons previously held more than five percent of shares of common stock of Marrone Bio Innovations, Inc. (“MBII”), immediately prior to the change of control transaction (the “Merger”) contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and MBII. Upon the consummation of the Merger, the shares of MBII held by the Reporting Persons were disposed of in exchange for the number of shares of Common Stock of the Issuer reported in this Schedule 13G.  

    Item 5.              Ownership of Five Percent or Less of a Class  

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x.  

    Item 6.              Ownership of More Than Five Percent on Behalf of Another Person

     

    Not applicable.  

    Item 7.              Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.  

     

    Not applicable.

     

    Item 8.              Identification and Classification of Members of the Group.

     

    See Exhibit 2.  

    Item 9.              Notice of Dissolution of Group.

    Not applicable.

     

     
    CUSIP No. G1117K114 13G Page 9 of 11 Pages

     

    Item 10. Certification
       
      The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Ardsley Advisory Partners LP:
       
    (a) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x 
       
    (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Ardsley Advisory Partners GP LLC:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x
       
    (c) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Ardsley Partners I GP LLC:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x
       
    (d) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Philip J Hempleman:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x
       
    (e) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Ardsley Partners Renewable Energy Fund, L.P.:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

     

     
    CUSIP No. G1117K114 13G Page 10 of 11 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      January 25, 2023  
      Date  
         
      ARDSLEY ADVISORY PARTNERS LP  
      By: Ardsley Advisory Partners GP LLC, its general partner  
         
      /s/ Steve Napoli  
      Signature  
         
      Steve Napoli/ Member  
      Name/Title  
         
      January 25, 2023  
      Date  
         
      ARDSLEY ADVISORY PARTNERS GP LLC  
         
      /s/ Steve Napoli  
      Signature  
         
      Steve Napoli/ Member  
      Name/Title  
         
      January 25, 2023  
      Date  
         
      ARDSLEY PARTNERS I GP LLC  
         
      /s/ Steve Napoli  
      Signature  
         
      Steve Napoli/ Member  
      Name/Title  

     

     
    CUSIP No. G1117K114 13G Page 11 of 11 Pages

     

      January 25, 2023  
      Date  
         
      PHILIP J. HEMPLEMAN  
         
      /s/ Steve Napoli*  
      Signature  
         
      Steve Napoli/Attorney-in Fact for Philip J. Hempleman  
      Name/Title  
         
      January 25, 2023  
      Date  
         
      ARDSLEY PARTNERS RENEWABLE ENERGY FUND, L.P.  
      By: Ardsley Partners I GP LLC, its general partner  
         
      /s/ Steve Napoli  
      Signature  
         
      Steve Napoli/ Member  
      Name/Title  

     

    * Executed by Steve Napoli as Attorney-in-Fact for Philip J. Hempleman. The Power of Attorney for Mr. Hempleman is attached as Exhibit 2 to the Statement on Schedule 13G with respect to the Common Stock of Vaxgen, Inc., filed on February 15, 2006, and is incorporated herein by reference.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $BIOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOX

    DatePrice TargetRatingAnalyst
    7/19/2024$17.00Buy
    Canaccord Genuity
    7/2/2024$15.00Buy
    ROTH MKM
    4/6/2023$15.00Outperform
    Oppenheimer
    9/30/2022$22.50Buy
    Canaccord Genuity
    10/8/2021$21.00Buy
    ROTH Capital
    More analyst ratings

    $BIOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on Bioceres with a new price target

      Canaccord Genuity resumed coverage of Bioceres with a rating of Buy and set a new price target of $17.00

      7/19/24 8:32:10 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • ROTH MKM resumed coverage on Bioceres with a new price target

      ROTH MKM resumed coverage of Bioceres with a rating of Buy and set a new price target of $15.00

      7/2/24 8:01:46 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Oppenheimer initiated coverage on Bioceres with a new price target

      Oppenheimer initiated coverage of Bioceres with a rating of Outperform and set a new price target of $15.00

      4/6/23 7:19:53 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

      Total revenues in 3Q25 were $60.6 million 3Q25 net loss was $1.6 million and Adjusted EBITDA1 was $9.0 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues were $60

      5/21/25 7:01:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions to Host Fiscal Third Quarter 2025 Financial Results Conference Call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal third quarter ended March 31, 2025. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube, Chief Commercial Officer Milen Marinov and Head of Investor Relations Paula Savanti will host the conference ca

      5/9/25 4:30:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Announces EPA Registration of Rinotec Insecticide and Nematicide Platform, a Game-Changing Solution for Integrated Pest Management

      Bioceres Crop Solutions (NASDAQ:BIOX), a leading global provider of sustainable crop productivity solutions, and ProFarm Group, a subsidiary of BIOX, today announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA's assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regi

      3/11/25 7:30:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Financials

    Live finance-specific insights

    See more
    • Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

      Total revenues in 3Q25 were $60.6 million 3Q25 net loss was $1.6 million and Adjusted EBITDA1 was $9.0 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues were $60

      5/21/25 7:01:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions to Host Fiscal Third Quarter 2025 Financial Results Conference Call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal third quarter ended March 31, 2025. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube, Chief Commercial Officer Milen Marinov and Head of Investor Relations Paula Savanti will host the conference ca

      5/9/25 4:30:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results

      Total revenues in 2Q25 were $106.7 million 2Q25 net income was $0.6 million and Adjusted EBITDA1 was $15.4 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal second quarter ended December 31, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Revenues in

      2/11/25 6:18:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bioceres Crop Solutions Corp.

      SC 13G - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      10/23/24 2:32:38 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp.

      SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      9/20/24 9:09:41 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp. (Amendment)

      SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      3/25/24 8:58:35 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    SEC Filings

    See more
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      5/21/25 4:44:06 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      3/11/25 4:01:14 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      2/12/25 8:04:36 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials